Status:
ACTIVE_NOT_RECRUITING
Multivariate Biomarker Study for Sarcopenia in Heart Failure
Lead Sponsor:
University of Liverpool
Collaborating Sponsors:
Liverpool Hope University
Liverpool University Hospitals NHS Foundation Trust
Conditions:
Heart Failure
Sarcopenia
Eligibility:
All Genders
50+ years
Brief Summary
In the United Kingdom, heart failure (HF) affects about 900,000 people with 60,000 new cases annually. Up to 60% of people living with HF also experience sarcopenia, known as loss of muscle mass and s...
Detailed Description
Investigators aim to understanding the underlying physiological links for secondary sarcopenia in older age and particularly those with heart failure. This links partly can be explained by impaired en...
Eligibility Criteria
Inclusion
- Inclusion criteria for HF:
- Clinically diagnosed HF regardless of ejection fraction rate (both HFrEF and HFpEF).
- Age 50 years and older.
- BMI more than 18 and less than 30 kg/m\^2.
- Must be on optimal medical treatment for three months prior to inclusion.
- Do not have contraindications to providing a blood sample.
- Sufficient mental capacity to consent as determined by the researchers.
- Able to walk with or without a walker for at least 16 m.
- No objection to the researchers contacting their general practitioner and neurologist.
- Exclusion criteria for HF:
- Receiving treatment with antibiotics, probiotics, or fish oil during the last 3 months prior to inclusion.
- Major comorbidities (i.e., cancer, Alzheimer's, type 2 diabetes, chronic kidney disease).
- Treatment with immunosuppressive drugs.
- Concurrent infections, or bowel disease.
- Patients who had received cardiac resynchronization therapy during the past 6 months will not be included.
- Participants must also not be on any other clinical trial during the study.
- Inclusion criteria for Healthy controls:
- No history of chronic disease and will be screened for hypertension.
- BMI more than 18 and less than 30 kg/m\^2.
- Although other cardiovascular conditions will be exclusionary, treated hypercholesterolemia and controlled hypertension will be allowed in the healthy group to allow the representation of elderly subjects within this cohort.
Exclusion
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06217640
Start Date
August 1 2023
End Date
December 30 2025
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liverpool University Hospitals NHS Foundation Trust
Liverpool, Merseyside, United Kingdom, L97AL